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Introduction (150 words) = 158 
We identified rare coding variants associated with Alzheimer’s disease 
(AD) in a 3-stage case-control study of 85,133 subjects. In stage 1, 34,174 
 9 
samples were genotyped using a whole-exome microarray. In stage 2, we 
tested associated variants (P<1x10-4) in 35,962 independent samples using de 
novo genotyping and imputed genotypes. In stage 3, an additional 14,997 
samples were used to test the most significant stage 2 associations (P<5x10-8) 
using imputed genotypes. We observed 3 novel genome-wide significant 
(GWS) AD associated non-synonymous variants; a protective variant in PLCG2 
(rs72824905/p.P522R, P=5.38x10-10, OR=0.68, MAFcases=0.0059, 
MAFcontrols=0.0093), a risk variant in ABI3 (rs616338/p.S209F, P=4.56x10-10, 
OR=1.43, MAFcases=0.011, MAFcontrols=0.008), and a novel GWS variant in TREM2 
(rs143332484/p.R62H, P=1.55x10-14, OR=1.67, MAFcases=0.0143, 
MAFcontrols=0.0089), a known AD susceptibility gene. These protein-coding 
changes are in genes highly expressed in microglia and highlight an immune-
related protein-protein interaction network enriched for previously identified 
AD risk genes. These genetic findings provide additional evidence that the 
microglia-mediated innate immune response contributes directly to AD 
development. 
 
 
 
 
 
 
Text (1500 words) = 1624 
Late-onset AD (LOAD) has a significant genetic component (h2=58-79%1). 
Nearly 30 LOAD susceptibility loci2–12 are known, and risk is significantly 
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polygenic13. However, these loci explain only a proportion of disease 
heritability. Rare variants also contribute to disease risk14–17. Recent 
sequencing studies identified a number of genes that have rare variants 
associated with AD9–11,18–24. Our approach to rare-variant discovery is to 
genotype a large sample with micro-arrays targeting known exome variants 
with follow-up using genotyping and imputed genotypes in a large 
independent sample. This is a cost-effective alternative to de novo 
sequencing25–29. 
We applied a 3-stage design (Supplementary Figure 1) using subjects 
from the International Genomics of Alzheimer’s Project (IGAP)(Table 1, 
Supplementary Tables 1 & 2). In stage 1, 16,097 LOAD cases and 18,077 
cognitively normal elderly controls were genotyped using the Illumina 
HumanExome microarray. Data from multiple consortia were combined in a 
single variant meta-analysis (Online Methods) assuming an additive model. In 
total, 241,551 variants passed quality-control (Supplementary Table 3). Of 
these 203,902 were polymorphic, 26,947 were common (minor allele 
frequency (MAF)≥5%), and 176,955 were low frequency or rare (MAF<5%). We 
analyzed common variants using a logistic regression model in each sample 
cohort and combined data using METAL30. Rare and low frequency variants 
were analyzed using the score test and data combined with SeqMeta31 
(Supplementary Figure 2). 
We reviewed cluster plots for variants showing association (P<1x10-4) 
and identified 43 candidate variants (Supplementary Table 4) exclusive of 
known risk loci (Supplementary Table 5). Stage 2 tested these for association in 
14,041 LOAD cases and 21,921 controls, using de novo and imputation derived 
genotypes (Online Methods). We carried forward single nucleotide variants 
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(SNVs) with GWS associations and consistent directions of effect to stage 3 
where genotypes for 6,652 independent cases and 8,345 controls were 
imputed using the Haplotype Reference Consortium resource32,33 (Online 
Methods, Supplementary Table 6). 
We identified four rare coding variants with GWS association signals 
with LOAD (P<5x10-8)(Table 2, Supplementary Tables 7 & 8). The first is a 
missense variant p.P522R (P=5.38x10-10, OR=0.68) in Phospholipase C Gamma 2 
(PLCG2)(Table 2, Figure 1a, Supplementary Table 9, Supplementary  Figure 3). 
This variant is associated with decreased risk of LOAD, showing a MAF of 
0.0059 in cases and 0.0093 in controls. The reference allele (p.P522) is 
conserved across several species (Supplementary Figure 4). Gene-wide analysis 
showed nominal evidence for association at P=1.52x10-4 (Supplementary 
Tables 10 & 11) and we found no other independent association at this gene 
(Supplementary Figure 5). 
The second novel association is a missense change p.S209F (P=4.56x10-
10, OR=1.43) in B3 domain-containing transcription factor ABI3 (ABI3). The 
p.F209 variant shows consistent evidence for increasing LOAD risk across all 
stages, with a MAF of 0.011 in cases and 0.008 in controls (Table 2, Figure 1b, 
Supplementary Table 12, Supplementary Figure 6). The reference allele is 
conserved across multiple species (Supplementary Figure 7). Gene-wide 
analysis showed nominal evidence of association (P=5.22x10-5)(Supplementary 
Tables 10 & 11). The B4GALNT2 gene, adjacent to ABI3, contained an 
independent suggestive association (Supplementary Figure 8), but this failed to 
replicate in subsequent stages (Pcombined=1.68x10-4)(Supplementary Table 7). 
Following reports of suggestive association with LOAD34,35, we report the 
first evidence for GWS association at TREM2 coding variant p.R62H (P=1.55x10-
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14, OR=1.67), with a MAF of 0.0143 in cases and 0.0089 in controls (Table 2, 
Figure 1c, Supplementary Table 13, Supplementary Figures 9 & 10). We also 
observed evidence for the previously reported9,11 TREM2 rare variant p.R47H 
(Table 2). These variants are not in linkage disequilibrium (Supplementary 
Table 14) and conditional analyses confirmed that p.R62H and p.R47H are 
independent risk variants (Supplementary Figure 11). Gene-wide analysis of 
TREM2 showed a GWS association (PSKAT=1.42x10-15)(Supplementary Tables 10 
& 11). Removal of p.R47H and p.R62H variants from the analysis diminished 
the gene-wide association but the signal remains interesting (PSKAT-O=6.3x10-3, 
PBurden=4.1x10-3). No single SNV was responsible for the remaining gene-wide 
association (Supplementary Table 13, Supplementary Figure 11) suggesting 
that there are additional TREM2 risk variants in TREM2. We previously 
reported a common variant LOAD association near TREM2, in a GWAS of 
cerebrospinal fluid tau and P-tau36. We also observed a different suggestive 
common variant signal in another LOAD case-control study (P=6.3x10-7)2.  
We previously identified 8 gene pathway clusters significantly enriched 
in AD-associated common variants36. To test whether biological enrichments 
observed in common variants are also present in rare variants we used the 
rare-variant data (MAF<1%) to reanalyze these eight AD-associated pathway 
clusters (Online Methods, Supplementary Table 15). We used Fisher’s method 
to combine gene-wide p-values for all genes in each cluster. After correction 
for multiple testing, we observed enrichment for immune response 
(P=8.64x10-3), cholesterol transport (P=3.84x10-5), hemostasis (P=2.10x10-3), 
Clathrin/AP2 adaptor complex (P=9.20x10-4) and protein folding (P=0.02). We 
also performed pathway analyses on the rare variant data presented here 
using all 9,816 pathways used previously. The top pathways are related to 
lipoprotein particles, cholesterol efflux, B-cell differentiation and immune 
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response, areas of biology also enriched when common variants are 
analyzed37(Supplementary Table 16). 
Previous analysis of normal brain co-expression networks identified 4 
gene modules that are enriched for common variants associated with LOAD 
risk2,3711. These 4 modules are enriched for immune response genes. We 
identified 151 genes present in 2 or more of these 4 modules and these 
showed a strong enrichment for LOAD-associated common variants (P=4.0x10-
6)36 and for rare variants described here (MAF<1%)(Supplementary Table 15, 
P=1.17x10-6). We then used a set of high-quality protein-protein interactions37 
to construct, from these 151 genes, an interaction network containing 56 
genes, including PLCG2, ABI3 and TREM2 (Figure 2)(Online Methods). This 
subset is strongly enriched for association signals from both the previous 
common variant analysis (P=5.0x10-6, Supplementary Table 17) and this rare 
variant gene-set analysis (P=1.08x10-7, Supplementary Table 15). The 
remaining 95 genes only have nominally-significant enrichment for either 
common or rare variants (Supplementary Tables 15 & 17), suggesting that the 
56-gene (Supplementary Table 18) network is driving the enrichment. 
TREM2, ABI3 and PLCG2 have a common expression pattern in human 
brain cortex, with high expression in microglia cells and limited expression in 
neurons, oligodendrocytes, astrocytes and endothelial cells (Supplementary 
Figure 12)38. Other known LOAD loci with the same expression pattern include 
SORL1, the MS4A gene cluster, and HLA-DRB1. PLCG2, ABI3, and TREM2 are 
up-regulated in LOAD human cortex and in two APP mouse models. However, 
when corrected for levels of other microglia genes, these changes in 
expression appear to be related to microgliosis (Supplementary Tables 19 & 
20).  
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PLCG2 (Supplementary Figure 13) encodes a transmembrane signaling 
enzyme (PLCɣ2) that hydrolyses the membrane phospholipid PIP2 (1-
phosphatidyl-1D-myo-inositol 4,5-bisphosphate) to secondary messengers IP3 
(myo-inositol 1,4,5-trisphosphate) and DAG (diacylglycerol). IP3 is released into 
the cytosol and acts at the endoplasmic reticulum where it binds to ligand-
gated ion channels to increase cytoplasmic Ca2+. DAG remains bound to the 
plasma membrane where it activates two major signaling molecules, protein 
kinase C (PKC) and Ras guanyl nucleotide-releasing proteins (RasGRPs), which 
initiate the NF-κB and mitogen-activated protein kinase (MAPK) pathways. 
While the IP3/DAG/Ca+2 signaling pathway is active in many cells and tissues, 
in brain, PLCG2 is primarily expressed in microglial cells. PLCG2 variants also 
cause Antibody Deficiency and Immune Dysregulation (PLAID) and 
Autoinflammation and PLAID (APLAID)39. Genomic deletions (PLAID) and 
missense mutations (APLAID) affect the cSH2 autoinhibitory regulatory region. 
The result is a complex mix of loss and gain of function in cellular signalling39.  
Functional annotation (Supplementary Table 21) suggests ABI3 
(Supplementary Figure 14) plays a role in the innate immune response via 
interferon-mediated signaling40. ABI3 is co-expressed with INPP5D (P=2.2x10-
10), a gene previously implicated in LOAD risk2. ABI3 plays a significant role in 
actin cytoskeleton organization through participation in the WAVE2 complex41, 
a complex that regulates multiple pathways leading to T-cell activation42. 
TREM2 encodes a transmembrane receptor present in the plasma 
membrane of brain microglia (Supplementary Figure 15). TREM2 protein forms 
an immune-receptor-signaling complex with DAP12. Receptor activation 
results in activation of Syk and ZAP70 signaling which in turn activates PI3K 
activity and influences PLCɣ2 activity43. In microglia, TREM2-DAP12 induces an 
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M2-like activation44 and participates in recognition of membrane debris and 
amyloid deposits resulting in microglial activation and proliferation45–47. When 
TREM2 knockout (KO) or TREM2 heterozygous KO mice are crossed with APP-
transgenics that develop plaques, the size and number of microglia associated 
with plaques are markedly reduced46,47. TREM2 risk variants are located within 
exon 2, which is predicted to encode the conserved ligand binding extracellular 
region of the protein. Any disruption in this region may attenuate or abolish 
TREM2 signaling, resulting in the loss or decrease in TREM2 function47. 
The 56-gene interaction network identified here is enriched in immune 
response genes and includes TREM2, PLCG2, ABI3, SPI1, INPP5D, CSF1R, SYK 
and TYROBP (Figure 2). SPI1 is a central transcription factor in microglial 
activation state that has a significant gene-wide association with AD5 and is in 
the proximity of GWS signals identified by IGAP2. Loss-of function mutations in 
CSF1R cause hereditary diffuse leukoencephalopathy with spheroids, a white 
matter disease related to microglial dysfunction48. Activated microglial cells 
surround plaques49,50, a finding consistently observed in AD brain and AD 
transgenic mouse models51. In AD mouse model brain, synaptic pruning 
associates with activated microglial signalling52. Pharmacological targeting of 
CSF1R inhibits microglial proliferation and shifts the microglial inflammatory 
profile to an anti-inflammatory phenotype in murine models53. SYK regulates 
Aβ production and tau hyperphosphorylation54, is affected by the 
INPP5D/CD2AP complex55 encoded by two LOAD associated genes2, and 
mediates phosphorylation of PLCG256. Notably, the anti-hypertensive drug 
Nilvadipine, currently in a phase III AD clinical trial, targets SYK as well as 
TYROBP, a hub gene in an AD-related brain expression network38,that encodes 
the TREM2 complex protein DAP12. 
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 We identified three rare coding variants in PLCG2, ABI3 and TREM2 with 
GWS associations with LOAD that are part of a common innate immune 
response. This work provides additional evidence that the microglial response 
in LOAD is directly part of a causal pathway leading to disease and is not simply 
a downstream consequence of neurodegeneration46,47,57,58. Our network 
analysis supports this conclusion. In addition, PLCɣG2, as an enzyme, 
represents the first classically drug-able target to emerge from LOAD genetic 
studies. The variants described here account for a small portion of the ‘missing 
heritability of AD’. The remaining heritability may be due to a large number of 
common variants of small effect size. For rare variants, there may be additional 
exonic sites with lower MAF or effect size, and/or intronic and intergenic sites. 
Complete resolution of AD heritability will be facilitated by larger sample sizes 
and more comprehensive sequence data.    
 
 
 
 
 
 
 
Data Availability 
Summary statistics for the 43 genetic associations identified are provided in 
Supplementary Table 6. 
Stage 1 data (individual level) for the GERAD exome chip cohort can be accessed by 
applying directly to Cardiff University. Stage 1 ADGC data is deposited in NIAGADS and 
NIA/NIH sanctioned qualified access data repository. Stage 1 CHARGE data is accessible by 
applying to dbGaP for all US cohorts, and to ERASMUS University for Rotterdam data. AGES 
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primary data are not available due to Icelandic laws. Stage 2 and stage 3 primary data is 
available upon request.  
A detailed description of the Mayo Clinic RNAseq data is available to all qualified 
investigators through the Accelerating Medicines Partnership in Alzheimer’s Disease (AMP-
AD) knowledge portal that is hosted in the Synapse software platform from Sage 
Bionetworks (Synapse IDs: syn3157182 and syn3435792 (mouse data), and  syn3163039 
(human data)). 
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Figure Legends 
Figure 1. Association plots of PLCG2, ABI3, and TREM2. (a) Regional plot of 
identified association at the PLCG2 locus. Top hit rs72824905 indicated in 
purple. Data presented for rs72824905 includes stage 1, stage 2 and stage 3 
(N=84,905). (b) Regional plot of identified association at the ABI3 locus. Top hit 
rs616338 indicated in purple. Data presented for rs616338 includes stage 1, 
stage 2 and stage 3 (N=84,493). (c) Regional plot of identified association at the 
TREM2 locus. Top hit rs75932628 indicated in purple. Data presented for 
rs75932628 and rs143332484 includes stage 1, stage 2 and stage 3 (N=80,733 
and 53,042, respectively). SNVs with missing LD information are shown in grey. 
 
Figure 2. Protein-protein interaction network (using high-confidence human 
interactions from the STRING database) of 56 genes enriched for both common 
and rare variants associated with AD risk. Colours of edges refer to the type of 
evidence linking the corresponding proteins: red=gene fusion, dark blue = co-
occurrence, black = co-expression, magenta = experiments, cyan=databases, 
light green = text mining, mauve = homology. TREM2, PLCG2 and ABI3 
highlighted by red circles, SYK, CSF1R and TYROBP highlighted by blue circles, 
and INPP5D, SPI1 and CD33 identified as common variant risk loci2,5–7, 
highlighted by black circles.  
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Table 1. Summary of the consortium data sets used for stages 1, 2 and stage 3. Data are from the Genetic and 1 
Environmental Risk for Alzheimer’s Disease (GERAD)/Defining Genetic, Polygenic and Environmental Risk for Alzheimer’s 2 
Disease (PERADES) Consortium, the Alzheimer’s Disease Genetic Consortium (ADGC), the Cohorts for Heart and Aging 3 
Research in Genomic Epidemiology (CHARGE) and the European Alzheimer’s disease Initiative (EADI)(Supplement 1). 4 
  Consortium  N Controls N Cases N Total 
Stage 1 GERAD/PERADES 2974 6000 8974 
  ADGC 7002 8706 15708 
  CHARGE 8101 1391 9492 
Total   18077 16097 34174 
Stage 2  GERAD/PERADES genotype 5049 4049 9098 
  CHARGE-genotype 1839 1434 3273 
 
CHARGE-in silico 3246 722 3968 
 EADI-genotype 11787 7836 19623 
Total   21921 14041 35962 
Stage 3  ADGC-in silico 8345 6652 14997 
Stage 1 + 2 + 3 
Total  
 
48402 37022 85133 
     
     
     
5 
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Table 2. Summary of stage 1, 2, 3 and combined meta-analysis results for SNVs 1 
at P<5x10-8. Data includes p-values, odds ratios (OR), minor allele frequency 2 
(MAF) in cases and controls and number of subjects included in each analytical 3 
stage. For OR 95% confidence intervals see Supplementary Table 7.  4 
SNV rs75932628 rs143332484 rs72824905 rs616338 
Chr 6 6 16 17 
Position 41129252 41129207 81942028 47297297 
Protein 
Variation 
R47H R62H P522R S209F 
Gene TREM2 TREM2 PLCG2 ABI3 
Effect Allele T T G T 
Stage 1 
P 3.02E-12 3.48E-09 1.19E-05 2.16E-05 
OR 2.46 1.58 0.65 1.42 
MAF Cases 0.003 0.015 0.006 0.013 
MAF Controls 0.001 0.010 0.011 0.010 
N 30018 33786 33786 33786 
Stage 2 
P 4.38E-08 3.66E-07 1.35E-04 8.37E-05 
OR 2.37 3.97 0.70 1.41 
MAF Cases 0.004 0.014 0.006 0.010 
MAF Controls 0.002 0.006 0.008 0.008 
N 35831 3968 35831 35831 
Stage 3 
P 1.23E-06 2.45E-03 2.48E-02 1.75E-02 
OR 2.58 1.55 0.69 1.58 
MAF Cases 0.006 0.012 0.006 0.010 
MAF Controls 0.003 0.008 0.007 0.008 
N 14884 15288 15288 14876 
Stage1, 2 and 3 Meta-Analysis 
 P 5.38E-24 1.55E-14 5.38E-10 4.56E-10 
OR 2.46 1.67 0.68 1.43 
MAF Cases 0.004 0.014 0.006 0.011 
MAF Controls 0.002 0.009 0.009 0.008 
N 80733 53042 84905 84493 
Note: Concordance for alternate allele carrier genotypes between imputed versus called 5 
SNPs in Stage 3 was 75.2% for rs75932628, 91.1% for rs143332484, 95.7% for rs72824905, 6 
and 81.9% for rs616338 (Online Methods and Supplementary Table 6). 7 
 35 
Online Methods 1 
Genotyping and Quality Control 2 
Stage 1 3 
GERAD/PERADES: Genotyping was performed at Life and Brain, Bonn, Germany, with 4 
the Illumina HumanExome BeadChip v1.0 (N=247,870 variants) or v1.1 (N=242,901 variants). 5 
Illumina’s GenTrain version 2.0 clustering algorithm in GenomeStudio or zCall1 was used for 6 
genotype calling. Quality control (QC) filters were implemented for sample call rate 7 
excluding samples with >1% missingness, excess autosomal heterozygosity excluding 8 
outliers based on <1% and >1% minor allele frequency (MAF) separately, gender 9 
discordance, relatedness excluding one of each pair related with IBD ≥ 0.125 (the level 10 
expected for first cousins), and population outliers (i.e. non European ancestry). Variants 11 
were filtered based on call rate excluding variants with >1% missingness, genotype cluster 12 
separation excluding variants with a separation score < 0.4 and Hardy-Weinberg equilibrium 13 
(HWE) excluding variants with PHWE < 1x10-4. Ten principal components (PCs) were extracted 14 
using EIGENSTRAT, including the first three PCs as covariates had the maximum impact on 15 
the genomic control inflation factor, λ2. After QC 6,000 LOAD cases and 2,974 elderly 16 
controls (version 1.0; 4,093 LOAD cases and 1,599 controls, version 1.1; 1,907 LOAD cases 17 
and 1,375 controls) remained. The version 1.0 array had 244,412 variants available for 18 
analysis and 239,814 remained for the version 1.1 array.  19 
CHARGE: All four CHARGE cohorts were genotyped for the Illumina HumanExome 20 
BeadChip v1.0. To increase the quality of the rare variant genotype calls, the genotypes for 21 
all four studies were jointly called with 62,266 samples from 11 studies at the University of 22 
Texas HSC at Houston3. Quality control (QC) procedures for the genotype data were 23 
performed both centrally at UT Houston and at each study. The central QC procedures have 24 
been described previously3. Minimum QC included: 1) Concordance checking with GWAS 25 
data and removal of problematic samples, 2) Removal of individuals with low genotype 26 
completion rate (<90%), 3) Removal of variants with low genotype call rate (<95%), 4) 27 
Removal of individuals with sex-mismatches, 5) Removal of one individual from duplicate 28 
pairs, 6) Removal of first-degree relatives based on genetically calculated relatedness (IBS > 29 
0.45), with cases retained over controls, 7) Removal of variants not called in over 5% of the 30 
individuals and those that deviated significantly form the expected Hardy-Weinberg 31 
Equilibrium proportions (P<1x10-6). 32 
ADGC: Genotyping was performed in subsets at four centers: NorthShore, Miami, 33 
WashU, and CHOP (“CHOP” and “ADC7” datasets) on the Illumina HumanExome BeadChip 34 
v1.0. One variant rs75932628 (p.R47H) in TREM2 clustered poorly across all ADGC cohorts, 35 
and was therefore re-genotyped using a Taqman assay. Data on all samples underwent 36 
standard quality control procedures applied to genome-wide association studies (GWAS), 37 
including excluding variants with call rates <95%, and then filtering samples with call rate 38 
<95%. Variants with MAF>0.01 were evaluated for departure from HWE and any variants for 39 
 36 
PHWE<10-6 were excluded. Population substructure within each of the five subsets 1 
(NorthShore, Miami, WashU, CHOP, and ADC7) was examined using PC analysis in 2 
EIGENSTRAT4, and population outliers (>6 SD) were excluded from further analyses; the first 3 
three PCs were adjusted for as covariates in association testing. Prior to analysis we 4 
harmonized the alternate and reference alleles over all datasets. See Supplementary Table 3 5 
for an overview of cohort genotype calling and quality control procedures. All sample 6 
genotyping and quality control was performed blind to participant’s disease status. 7 
 8 
Stage 2  9 
Twenty-two variants successfully designed for replication genotyping on the Agena 10 
Bioscience MassARRAY® platform. Genotyping was performed at Life and Brain, Bonn, 11 
Germany, and the Centre National de Génotypage (CNG), Paris, France. Twenty-one variants 12 
were successfully genotyped, with one variant (rs147163004 in ASTN2) failing visual cluster 13 
plot inspection. An additional nine variants were successfully genotyped using the Agena 14 
Bioscience MassARRAY® platform or Thermo FisherTaqMan® assay at the CNG, Paris, France 15 
in a subset of the replication samples N=16,850 (7,755 cases, 9,095 controls). 16 
GERAD/PERADES and ACE QC: Filters were implemented for sample call rate, 17 
excluding samples with >10% missingness, and excess autosomal heterozygosity via visual 18 
inspection. Variants were filtered based on call rate excluding variants with >10% 19 
missingness and HWE excluding variants with PHWE<1x10-5 in either cases or controls.  20 
IGAP and EADI QC: Variants were genotyped in 3 different panels and QC was 21 
performed in each panel separately. Samples with more than 3 missing genotypes were 22 
excluded, as were males heterozygous for X-Chromosome variants present within the 23 
genotyped panels. Variants were excluded based on missingness >5%, HWE (in cases and 24 
controls separately) <1x10-5, and differential missingness between cases and controls <1x10-25 
5, for each Country cohort. All variants passed quality control. PCs were determined using 26 
previously described methods19.  27 
 28 
Stage 3  29 
Replication was performed using genotypes from 23 ADGC datasets as described 30 
above. Genotyping arrays used have been described in detail before for most datasets, 31 
except for the CHAP, NBB, TARCC, and WHICAP datasets. CHAP and WHICAP datasets were 32 
genotyped on the Illumina OmniExpress-24 array, while NBB was genotyped on the Illumina 33 
1M platform. TARCC first wave subjects were genotyped using the Affymetrix 6.0 microarray 34 
chip, while subjects in the second wave (172 cases and 74 controls) were genotyped using 35 
the Illumina HumanOmniExpress-24 beadchip. Second wave TARCC subjects (TARCC2) were 36 
genotyped together with 84 cases and 115 controls from second wave samples ascertained 37 
 37 
at the University of Miami and Vanderbilt University. All samples used in stage 3 were 1 
imputed to the HRC haplotype reference panel5,6, which includes 64,976 haplotypes with 2 
39,235,157 SNPs that allows imputation down to an unprecedented MAF=0.00008. 3 
Prior to imputation, all genotype data underwent QC procedures that have been 4 
described extensively elsewhere7,8. Imputation was performed on the Michigan Imputation 5 
Server (https://imputationserver.sph.umich.edu/) running MiniMac39,10.Genotypes from 6 
genome-wide, high-density SNP genotyping arrays for 16,175 AD cases and 17,176 7 
cognitive-normal individuals were imputed. Across all samples 39,235,157 SNPs were 8 
imputed, with the actual number of SNPs imputed for each individual varying based on the 9 
regional density of array genotypes available. As a subset of these samples had also been 10 
genotyped as part of stage 1, we examined the imputation quality for critical variants by 11 
comparing imputed genotypes to those directly genotyped by the exome array; overall 12 
concordance was >99%, while concordance among alternate allele genotypes 13 
(heterozygotes and alternate allele homozygotes) was >88.5% on average (N=13,000 14 
samples).  Concordance between Stage 3 imputed genotypes and exome chip genotypes for 15 
replicated SNPs is reported in Supplementary Table 6. 16 
 17 
Analysis 18 
Stage 1 19 
We tested association with LOAD using logistic regression modelling for common 20 
and low frequency variants (MAF>1%) and implementing maximum likelihood estimation 21 
using the score test and ‘seqMeta’ package for rare variation (MAF≤1%). Analyses were 22 
conducted globally in the GERAD/PERADES consortium, and for each contributing centre in 23 
the CHARGE and ADGC consortia under two models (1) an ‘unadjusted’ model, which 24 
included minimal adjustment for possible population stratification, using Country of origin 25 
and the first three principal components from PCA, and (2) an ‘adjusted’ model, which 26 
included covariates for age, and sex, as well as Country of origin and the first three principal 27 
components. Age was defined as the age at onset of clinical symptoms for cases, and the 28 
age at last interview for cognitively normal controls. 29 
Meta-analysis for common and low frequency variants were undertaken in METAL 30 
using a fixed-effects inverse variance-weighted meta-analysis. Rare variants were meta-31 
analysed in the SeqMeta R package. In the SeqMeta pipeline, cohort-level analyses 32 
generated score statistics through the function ‘prepScores()’ which were captured in *. 33 
Rdata objects. These *. Rdata objects contain the necessary information to meta-analyse 34 
SKAT analyses: the individual SNP scores, MAF, and a covariance matrix for each unit of 35 
aggregation. Using the ‘singlesnpMeta()’ and ‘skatOmeta()’ functions of SeqMeta, the *. 36 
Rdata objects for individual studies were meta-analysed. The seqMeta coefficients and 37 
standard errors can be interpreted as a ‘one-step‘ approximation to the maximum likelihood 38 
 38 
estimates. Monomorphic variants in individual studies were not excluded as they contribute 1 
to the minor allele frequency information. Three independent analysts confirmed the meta-2 
analysis results.  3 
In the GERAD/PERADES consortium 1,740 participants (888 LOAD cases and 852 4 
controls) did not have age information available and were excluded from the adjusted 5 
analyses. Therefore, 16,160 cases and 17,967 controls were included in the unadjusted 6 
analyses and 15,272 cases and 17,115 controls were included in the adjusted analyses. The 7 
primary analysis utilized the unadjusted model given the larger sample size this provided. 8 
See Supplementary Figure 2 for QQ plots of unadjusted and adjusted analyses. 9 
 10 
Stage 2  11 
We tested association with LOAD using the score test and ‘seqMeta’ package. 12 
Analyses were conducted under the two models described above, in the analysis groups 13 
indicated in Supplementary Table 2. Analyses were undertaken globally in the 14 
GERAD/PERADES cohort and by Country in the IGAP cohorts, with the EADI1 cohort only 15 
including French participants and the ACE cohort including only Spanish participants. 16 
Following the format of the IGAP mega meta-analysis7, four PCs were included for the EADI1 17 
dataset, and one in the Italian and Swedish IGAP clusters. Meta-analysis was undertaken in 18 
the SeqMeta R package.  19 
 20 
 Stage 3  21 
Association analyses performed followed Stage 1 and Stage 2 analytical procedures 22 
described below, and only variants in ABI3, PLCG2 and TREM2 were examined. For gene-23 
based testing, 10 variants in ABI3, 35 in PLCG2, and 13 in TREM2 were examined. 24 
 25 
Pathway/Gene-set Enrichment Analysis  26 
The eight biological pathway clusters previously identified as enriched for 27 
association in the IGAP dataset11 were tested for enrichment in this rare variation study 28 
(Supplementary Table 15) in order to test whether the biological enrichments observed in 29 
common variants also apply to rare variants. Genes were defined without surrounding 30 
genomic sequence, as this yielded the most significant excess of enriched pathways in the 31 
common variation dataset11. Gene-wide SKAT-O P-values for the variants of interest were 32 
combined using the Fisher’s combined probability test.  Given the low degree of LD12 33 
between rare variants our primary analyses did not control for LD between pathway genes. 34 
However, as a secondary analysis, the APOE region was removed, and for each pair of 35 
pathway genes within 1Mb of each other, the gene with the more significant SKAT-O P-36 
 39 
value was removed. This highly conservative procedure removes any potential bias in the 1 
enrichment test both from LD between the genes, and also from dropping less significant 2 
genes from the analysis.  3 
We also performed pathway analyses on the rare variant data presented here using 4 
all 9,816 pathways used previously.  The top pathways are related to lipoprotein particles, 5 
cholesterol efflux, B-cell differentiation and immune response, and closely parallel the 6 
common variant results (Supplementary Table 16). 7 
 8 
Protein interaction Analysis 9 
Previous analysis of normal brain co-expression networks identified 4 gene modules 10 
that were enriched for common variants associated with AD risk in the IGAP GWAS. Each of 11 
these 4 modules was also found to be enriched for immune-related genes. The 151 genes 12 
present in 2 or more of these 4 modules were particularly strongly enriched for IGAP GWAS 13 
association41. This set of 151 co-expressed genes thus contains genes of relevance to AD 14 
aetiology. To identify these genes, and clarify biological relationships between them for 15 
future study, protein interaction analysis was performed. First, a list of high-confidence 16 
(confidence score >0.7) human protein-protein interactions was downloaded from the latest 17 
version (v10) of the STRING database (http://string-db.org). Then, protein interaction 18 
networks were generated as follows: 19 
1. Choose a gene to start the network (the “seed” gene) 20 
2. For each remaining gene in the set of 151 genes, add it to the network if its 21 
corresponding protein shows a high-confidence protein interaction with a 22 
protein corresponding to any gene already in the network. 23 
3. Repeat step 2 until no more genes can be added  24 
4. Note the number of genes in the network 25 
5. Repeat, choosing each of the 151 genes in turn as the seed gene. 26 
 27 
The largest protein interaction network resulting from this procedure resulted in a 28 
network of 56 genes connected by high-confidence protein interactions. To test whether 29 
this network was larger than expected by chance, given the total number of protein-protein 30 
interactions for each gene, random sets of 151 genes were generated, with each gene 31 
chosen to have the same total number of protein-protein interactions as the corresponding 32 
gene in the actual data. Protein networks were generated for each gene as described above, 33 
and the size of the largest such network compared to the observed 56-gene network. 1000 34 
random gene sets were generated, and none of them yielded a protein interaction network 35 
as large as 56 genes.  Note that the procedure for generating the protein interaction 36 
network relies only on protein interaction data, and is agnostic to the strength of GWAS or 37 
 40 
rare-variant association for each gene. Thus the strength of genetic association in the set of 1 
56 network genes can be tested relative to that in the original set of 151 genes without bias.   2 
 3 
Gene-set enrichment analysis of the protein network 4 
The set of 56 network genes was tested for association enrichment in the IGAP 5 
GWAS using ALIGATOR13, as was done in the original pathway analysis, using a range of p-6 
value thresholds for defining significant SNPs (and thus the genes containing those SNPs). 7 
The same analysis was also performed on the 95 genes in the module overlap but not the 8 
protein interaction network (Supplementary Table 17). It can be seen that the 56 network 9 
genes account for most of the enrichment signal observed in the set of 151 module overlap 10 
genes. 11 
The set of 56 network genes, the set of 151 module overlap genes, and the set of 95 12 
genes in the module overlap but not the network were tested for enrichment of association 13 
signal in variants with MAF<1% using the gene set enrichment method described above in 14 
section 11. Both the set of 151 genes (P=1.17x10-6) and the subset of 56 genes (P =1.08x10-15 
7) show highly significant enrichment for association in the rare variants with MAF<1%. It 16 
can be seen that the 56 network genes account for most of the enrichment signal observed 17 
in the set of 151 module overlap genes (Supplementary Table 17). Again, the subset of 56 18 
genes accounts for most of the enrichment signal observed in the set of 151 genes, as the 19 
remaining 95 genes have only nominally-significant enrichment (P=0.043). Both the set of 20 
151 genes (P=5.15x10-5) and the subset of 56 genes (P=2.98x10-7) show significant 21 
enrichment under a conservative analysis excluding the APOE region and correcting for 22 
possible LD between the genes (Supplementary Table 17). Thus, the rare variants show 23 
convincing replication of the biological signal observed in the common variant GWAS, and 24 
furthermore, the protein network analysis has refined this signal to a set of 56 interacting 25 
genes. Given that TREM2 has a highly significant gene-wide p-value (P=1.01x10-13) among 26 
variants with MAF<1%, enrichment analyses were run omitting it. Both the set of 151 genes 27 
(P=2.78x10-3) and the subset of 56 genes (P=0.010) (Supplementary Table 18) still showed 28 
significant enrichment of signal, suggesting that the contribution of rare variants to disease 29 
susceptibility in these networks is not restricted to TREM2. Biological follow-up of genetic 30 
results is labour-intensive and expensive. It is therefore important to concentrate such work 31 
on the genes that are most important to AD susceptibility. Thus, the rationale for reducing 32 
the gene set is that it defines a network of genes that are not only related through co-33 
expression and protein interaction, but also show enrichment for genetic association signal. 34 
These genes are therefore strong candidates for future biological study. 35 
 36 
 37 
 38 
 41 
Gene Expression 1 
We examined mRNA expression of the novel genes PLCG2 and ABI3 in 2 
neuropathologically characterized brain post-mortem tissue (508 persons): they are 3 
expressed at low levels in the dorsolateral prefrontal cortex of subjects from two studies of 4 
aging with prospective autopsy (ranked 12,965th out of 13,484 expressed genes)14. 5 
However, ABI3 and PLCG2 were more highly expressed in purified microglia/macrophage 6 
from the cortex of 11 subjects from these cohorts (1740th and 2600th respectively out of 7 
the 11,500 expressed genes)(unpublished data). These findings are consistent with the high 8 
levels of expression of both PLCG2 and ABI3 in peripheral monocytes, spleen, and whole 9 
blood reported by the ROADmap project and in microglia as reported by Zhang et al15. From 10 
the same brain tissue, we examined methylation (n=714)16 and H3K9ac acetylation (n=676) 11 
data and found differential methylation at four CpG sites and lower acetylation at two 12 
H3K9ac sites adjacent to PLCG2 and ABI3 in relation to increased global neuritic plaque and 13 
tangle burden (FDR < 0.05). Similarly, high TREM2 expression has been shown to correlate 14 
with increasing neuritic plaque burden17. 15 
 16 
AMP-AD Gene Expression Data: RNA sequencing was used to measure gene 17 
expression levels in the temporal cortex of 80 subjects with pathologically confirmed AD and 18 
76 controls without any neurodegenerative pathologies obtained from the Mayo Clinic Brain 19 
Bank and the Banner Sun Health Institute. The human RNA sequencing data is deposited in 20 
the Accelerating Medicines Partnership-AD (AMP-AD) knowledge portal housed in Synapse 21 
(https://www.synapse.org/#!Synapse:syn2580853/wiki/66722). After QC, our postmortem 22 
human cohort has 80 subjects with pathologically confirmed AD and 76 controls without any 23 
neurodegenerative pathologies. Assuming two samples of 100 per group, two-sample t-test, 24 
same standard deviation, we will have 80% power to detect effect sizes of 0.40, 0.49 and 25 
0.59 at p<0.05, 0.01 and 0.001, respectively, where effect size is the difference in means 26 
between two groups divided by the within-group standard deviation. The human RNA 27 
sequencing data overview, QC and analytic methods are available at the following Synapse 28 
pages, respectively: syn3163039, syn6126114, syn6090802. Multivariable linear regression 29 
was used to test for association of gene expression levels with AD diagnosis (Dx) using two 30 
different models: In the Simple model, we adjust for age at death, sex, RNA integrity 31 
number (RIN), tissue source, and RNAseq flowcell. In the Comprehensive model, we adjust 32 
for all these covariates, and brain cell type markers for five cell-specific genes (CD68 33 
(microglia), CD34 (endothelial), OLIG2 (oligodendroglia), GFAP (astrocyte), ENO2 (neuron)) 34 
to account for cell number changes that occur with AD neuropathology. TREM2, PLCG2 and 35 
ABI3 are significantly higher in AD temporal cortex prior to correcting for cell types (Simple 36 
model), but this significance is abolished after adjusting for cell-specific gene counts 37 
(Comprehensive model). This suggests that these elevations are likely a consequence of 38 
changes in cell types that occur with AD, most likely microgliosis given that TREM2, PLCG2 39 
 42 
and ABI3 are microglia-enriched genes15 (Supplementary Table 19, Supplementary Figure 1 
12).  2 
 3 
 4 
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